Rechanneling the Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development Without the Thorough QT Study
July 23, 2013
Silver Spring, Maryland, USA
The mission of the HESI Cardiac Safety Committee is to improve public health by reducing unanticipated cardiovascular-related adverse effects from drugs or chemicals, and to develop innovative approaches to support early detection and prediction as well as improved understanding of cardiovascular toxicology and pathobiology.
National Institute of Environmental Health Sciences, National Toxicology Program
US Food and Drug Administration
July 23, 2013
Silver Spring, Maryland, USA
March 18, 2013 – March 19, 2013
Cambridge, Massachusetts, USA
This workshop was co-sponsored by co-sponsored by the HESI Cardiac Safety Technical Committee and the Safety Pharmacology Society.
October 4, 2012
Phoenix, Arizona, USA
This event was sponsored by the HESI Technical Committee on Cardiac Safety.
October 6, 2008 – October 7, 2008
Washington, DC, USA
This event was sponsored by the HESI Cardiac Safety Committee.
September 22, 2008 – September 25, 2008
Madison, Wisconsin, USA
The HESI Cardiac Safety Technical Committee presented gave two presentations (“A HESI Consortium Approach to Assess the Human Predictive Value of Non-Clinical Repolarization Assays") at this event.
February 14, 2008 – February 15, 2008
Washington, DC, USA
This workshop was sponsored by the HESI Biomarkers of Toxicity Committee.
Regulatory Toxicology and Pharmacology, 2020
Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models to study the electrophysiological effects of novel drug candidates on human ventricular repolarization. Two recent large validation studies have demonstrated the ability of hSC-CMs to detect drug-induced delayed ...
Journal of Pharmacological and Toxicological Methods, 2020
Zucker diabetic fatty (ZDF) rats are used widely as an animal model of metabolic syndrome and insulin resistance. Our study focused on the effects of high versus low dietary fat on the development of Type 2 diabetes in obese male ZDF rats (fa/fa), including biomarkers to detect early signs of hypercoagulability and vascular injury ...
Journal of Pharmacological and Toxicological Methods, 2020
Alterations in cardiac contractility can have significant clinical implications, highlighting the need for early detection of potential liabilities. Pre-clinical methods to assess contractility are typically invasive and their translation to human measures of cardiac function are not well defined. Clinically, cardiac ...
Nature Scientific Reports, 2020
Automated patch clamp (APC) instruments enable efficient evaluation of electrophysiologic effects of drugs on human cardiac currents in heterologous expression systems. Differences in experimental protocols, instruments, and dissimilar site procedures affect the variability of IC50 values characterizing drug block ...
Journal of Pharmacological and Toxicological Methods, 2019
Voltage-sensitive optical (VSO) sensors offer a minimally invasive method to study the time course of repolarization of the cardiac action potential (AP). This Comprehensive in vitro Proarrhythmia Assay (CiPA) cross-platform study investigates protocol design and measurement variability of VSO sensors for ...
Frontiers in Pharmacology, 2019
Contractility of the myocardium engines the pumping function of the heart and is enabled by the collective contractile activity of its muscle cells: cardiomyocytes. The effects of drugs on the contractility of human cardiomyocytes in vitro can provide mechanistic insight that can support the prediction of clinical cardiac drug ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.